Page last updated: 2024-10-22

amodiaquine and Vomiting

amodiaquine has been researched along with Vomiting in 6 studies

Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.

Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.

Research Excerpts

ExcerptRelevanceReference
"Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations."9.51Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022)
"Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations."5.51Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022)
"Seven patients developed hepatitis after receiving amodiaquine for malaria prophylaxis for 4 to 15 weeks."3.67Amodiaquine-induced hepatitis. A report of seven cases. ( Benhamou, JP; Castot, A; Feldmann, G; Larrey, D; Lenoir, A; Machayekhy, JP; Merigot, P; Pëssayre, D; Rueff, B, 1986)
"Methylene blue (MB) was the first synthetic antimalarial drug ever used, and recent studies have been promising with regard to its revival in malaria therapy."2.73Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. ( Coulibaly, B; Klose, C; Kouyaté, B; Mansmann, U; Meissner, P; Mockenhaupt, FP; Müller, O; Schirmer, RH; Sié, A; Walter-Sack, I; Zoungrana, A, 2008)
" No significant adverse event attributable to any of the study drugs was found."2.73Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. ( Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008)
"Vomiting was more frequent in the artesunate + amodiaquine on D1 and D2."1.32[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi]. ( Barihuta, T; Barutwanayo, M; Bosman, A; Ciza, A; Delacollette, C; Kamana, J; Karenzo, J; Mizero, L; Moyou-Somo, R; Nahimana, A; Ndaruhutse, J; Ndayiragije, A; Niyungeko, D; Niyungeko, E; Nyarushatsi, JP; Ringwald, P, 2004)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Peto, TJ1
Tripura, R1
Callery, JJ1
Lek, D1
Nghia, HDT1
Nguon, C1
Thuong, NTH1
van der Pluijm, RW1
Dung, NTP1
Sokha, M1
Van Luong, V1
Long, LT1
Sovann, Y1
Duanguppama, J1
Waithira, N1
Hoglund, RM1
Chotsiri, P1
Chau, NH1
Ruecker, A1
Amaratunga, C1
Dhorda, M1
Miotto, O1
Maude, RJ1
Rekol, H1
Chotivanich, K1
Tarning, J1
von Seidlein, L1
Imwong, M1
Mukaka, M1
Day, NPJ1
Hien, TT1
White, NJ1
Dondorp, AM1
Ndayiragije, A1
Niyungeko, D1
Karenzo, J1
Niyungeko, E1
Barutwanayo, M1
Ciza, A1
Bosman, A1
Moyou-Somo, R1
Nahimana, A1
Nyarushatsi, JP1
Barihuta, T1
Mizero, L1
Ndaruhutse, J1
Delacollette, C1
Ringwald, P1
Kamana, J1
Zoungrana, A1
Coulibaly, B1
Sié, A1
Walter-Sack, I1
Mockenhaupt, FP1
Kouyaté, B1
Schirmer, RH1
Klose, C1
Mansmann, U1
Meissner, P1
Müller, O1
Djimdé, AA1
Fofana, B1
Sagara, I1
Sidibe, B1
Toure, S1
Dembele, D1
Dama, S1
Ouologuem, D1
Dicko, A1
Doumbo, OK1
Talani, P1
Samba, G1
Moyen, G1
Larrey, D1
Castot, A1
Pëssayre, D1
Merigot, P1
Machayekhy, JP1
Feldmann, G1
Lenoir, A1
Rueff, B1
Benhamou, JP1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and [NCT03355664]Phase 3310 participants (Actual)Interventional2018-03-19Completed
[NCT00354380]Phase 20 participants Interventional2006-09-30Completed
A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218]Phase 35,920 participants (Actual)Interventional2017-04-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fever Clearance Time

The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours (NCT03355664)
Timeframe: 42 day

InterventionHours to fever clearance (Mean)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 2418.3
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 2414.9

Incidence of Adverse Events Concerning Markers of Hepatic or Renal Toxicity

Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured (NCT03355664)
Timeframe: 42 day

InterventionEvents (Number)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 2453
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 2463

Incidence of Prolongation of the Corrected QT Interval

We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. (NCT03355664)
Timeframe: 28 day

InterventionEvents (Number)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 240
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 240

Number of Severe Adverse Events by Study Arm

"All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events. The AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.~All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis. Secondary outcomes not involving the randomised comparison will be updated when the analyses are available. Please note that analyses of these Secondary outcomes will take time." (NCT03355664)
Timeframe: 42 days

InterventionParticipants (Number)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 242
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 245

Parasite Clearance Half-life

Parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance (NCT03355664)
Timeframe: 42 day

InterventionHours (Mean)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 245
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 245.5

Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm

Efficacy is defined as participants, following initial parasite and fever clearance, not having a recrudescence of the original plasmodium infection and fever, up to 42 days of follow up. (NCT03355664)
Timeframe: 42 days

InterventionParticipants (Count of Participants)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24146
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24151

Prolongation of the Corrected QT Interval

We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. There were zero events of this at any time point in either study arm. So no further analyses are possible. (NCT03355664)
Timeframe: Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points

InterventionEvents (Number)
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 240
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 240

42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region

42-day polymerase chain reaction corrected efficacy defined as adequate clinical and parasitological response (ACPR) according to site/geographic region. (NCT03355664)
Timeframe: 42 day

,
InterventionParticipants (Count of Participants)
West CambodiaEast CambodiaVietnam
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24359026
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24329123

Incidence of Clinical Episodes of Malaria

Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.

InterventionNo. of events/1000 person years at risk (Number)
SMC With SP+AQ304.8
RTS,S/AS01278.2
RTS,S/AS01 PLUS SMC With SP+AQ113.3

Trials

3 trials available for amodiaquine and Vomiting

ArticleYear
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
    The Lancet. Infectious diseases, 2022, Volume: 22, Issue:6

    Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Dru

2022
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
    PloS one, 2008, Feb-20, Volume: 3, Issue:2

    Topics: Amodiaquine; Artemisinins; Artesunate; Burkina Faso; Drug Therapy, Combination; Drug-Related Side Ef

2008
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
    The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:3

    Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Biomarkers; Drug Combinations; Drug R

2008

Other Studies

3 other studies available for amodiaquine and Vomiting

ArticleYear
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi].
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:6

    Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Burundi; Child, Preschool; Drug Re

2004
[Management of child fever in the battle against malaria in Brazzaville].
    Bulletin de la Societe de pathologie exotique (1990), 2002, Volume: 95, Issue:1

    Topics: Amodiaquine; Antimalarials; Asthenia; Child, Preschool; Chills; Chloroquine; Congo; Diarrhea; Fever;

2002
Amodiaquine-induced hepatitis. A report of seven cases.
    Annals of internal medicine, 1986, Volume: 104, Issue:6

    Topics: Adult; Alanine Transaminase; Amodiaquine; Aspartate Aminotransferases; Asthenia; Chemical and Drug I

1986